Periurethral abscess following polyacrylamide hydrogel (Bulkamid) for stress urinary incontinence.

D Gopinath, AR Smith, FM Reid

Research output: Contribution to journalArticlepeer-review


Bulkamid® is a periurethral bulking agent used to treat stress urinary incontinence (SUI). Manufacturers describe it as nontoxic, nonbiodegradable and biocompatible. Periurethral abscesses are one of the known complications of bulking agents. We present the first reported case of periurethral abscess following Bulkamid® injection. The woman had previously had a transobturator tape (TOT) and total vaginal mesh repair. At 6 weeks after injection of the bulking agent, she reported 100 % cure of her SUI. Transperineal ultrasound was used to diagnose and monitor an abscess that developed anterior and lateral to the urethra and separate from the TOT. Magnetic resonance imaging was helpful in delineating the extent of the abscess into the retropubic space but was not able to identify the urethra or the TOT. Surgical drainage of the abscess was performed vaginally, resulting in successful resolution of pain but recurrence of incontinence.
Original languageEnglish
Pages (from-to)1645-1648
Number of pages4
JournalInternational Urogynecology Journal
Publication statusPublished - Nov 2012


Dive into the research topics of 'Periurethral abscess following polyacrylamide hydrogel (Bulkamid) for stress urinary incontinence.'. Together they form a unique fingerprint.

Cite this